Dupilumab

GPTKB entity

Statements (57)
Predicate Object
gptkbp:instance_of gptkb:monoclonal_antibody
gptkbp:administered_by subcutaneous injection
gptkbp:approves gptkb:2017
gptkb:FDA
gptkbp:availability prescription only
gptkbp:chemical_formula C30 H32 N6 O7 S
gptkbp:clinical_trial Phase 3
gptkbp:clinical_use long-term management
gptkbp:contraindication hypersensitivity to dupilumab
gptkbp:developed_by gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
gptkbp:financial_stability stable until expiration date
gptkbp:formulation solution for injection
https://www.w3.org/2000/01/rdf-schema#label Dupilumab
gptkbp:indication chronic rhinosinusitis with nasal polyps
moderate to severe atopic dermatitis
eosinophilic esophagitis
moderate to severe asthma
gptkbp:interacts_with no significant drug interactions
gptkbp:invention patented
gptkbp:is_monitored_by monitor for allergic reactions
monitor for eosinophilia
monitor for ocular symptoms
gptkbp:marketed_as gptkb:Dupixent
gptkbp:mechanism_of_action inhibits IL-4 and IL-13 signaling
gptkbp:packaging auto-injector
pre-filled syringe
gptkbp:patient_education importance of adherence to therapy
advise on potential side effects
instruct on injection technique
gptkbp:patient_population adults
children over 6 years old
gptkbp:pharmacokinetics half-life of approximately 26 days
gptkbp:price high cost
gptkbp:provides_guidance_on included in treatment guidelines
gptkbp:research_focus autoimmune diseases
allergic diseases
chronic inflammatory diseases
gptkbp:route_of_administration subcutaneous
gptkbp:safety_features generally well tolerated
gptkbp:service_frequency every 2 weeks
initial loading dose
gptkbp:side_effect headache
urticaria
injection site reactions
conjunctivitis
pharyngitis
gptkbp:storage refrigerated at 2-8° C
gptkbp:targets gptkb:IL-13_receptor
gptkb:IL-4_receptor
gptkbp:used_for gptkb:asthma
atopic dermatitis
chronic rhinosinusitis with nasal polyps
gptkbp:weight 600.7 g/mol
gptkbp:bfsParent gptkb:EMD_Serono
gptkb:Dupixent
gptkbp:bfsLayer 5